MET and cancer: Although HGF/c‐MET targeted therapy has facilitated breakthroughs in some cancers, a single therapy targeting HGF/c‐MET has failed to show significant clinical efficacy in most cancers, suggesting that we need to find new therapeutic targets to improve the therapeutic efficiency of inhibitors and provide patients with precise treatment [30].